• Altimmune presented positive Phase 2 RECLAIM results for investigational pemvidutide in adults with moderate-to-severe alcohol use disorder at AASLD’s Liver Meeting 2026.
• Treatment significantly reduced heavy drinking versus placebo, meeting the primary endpoint; abstinence also improved.
• Pemvidutide was generally well tolerated, with mostly mild-to-moderate adverse events; treatment discontinuation rates were comparable with placebo.
• Additional Phase 2b IMPACT results presented showed improvements in liver fibrosis markers in patients with metabolic dysfunction-associated steatohepatitis.
• An FDA meeting is scheduled for December to discuss the Phase 3 registrational program design for alcohol use disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091230PRIMZONEFULLFEED9872858) on November 09, 2026, and is solely responsible for the information contained therein.